GlaxoSmithKline(GSK) said on Thursday that a “Pre-Clinical Analysis” of the antibody-based COVID-19 therapy which is developing with US partner Vir has indicated that the drug also works against the new Omicron variant.
GSk Further said tests will be carried out on the “Sotrovimab Therapy” to ascertain the results. The drug regulator of Britain meanwhile approved GSK (GSK.L) and Vir Biotechnology’s (VIR.O) antibody-based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.
